NCT02311621

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2014-11-25Est. Completion: 2023-11

Enrollment target: 65 participants

Locations

Neuroblastoma

The survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a hig…

Guangzhou, ChinaCompleted Feb 4, 2026

Recurrent GanglioneuroblastomaRecurrent NeuroblastomaRefractory GanglioneuroblastomaRefractory Neuroblastoma

This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy d…

Multiple LocationsEst. completion Sep 30, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.